Psyched Wellness (PSYC) AI Stock Analysis

• Market Cap: C$2.89M
• Dividend Yield: N/A
• Average Volume (3M): 81.03K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.26
• Revenue Growth: -41.18%
• EPS Growth: 17.65%
• Country: CA
• Employees: 1,800
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): >-0.01
• Shares Outstanding: 288,816,830
• 10 Day Avg. Volume: 36,477
• 30 Day Avg. Volume: 81,030
• PEG Ratio: 0.07
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 7.62
• P/FCF Ratio: -1.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.02 ▼(-25.00% Downside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is held down primarily by heavy losses and ongoing cash burn despite strong revenue growth, with weak technical momentum adding pressure. A debt-free balance sheet and a positive product-related corporate update provide partial offsets, but valuation support is limited due to negative earnings and no dividend.

Psyched Wellness Business Overview & Revenue Model

Company Description

Psyched Wellness Ltd., a health supplements company, engages in the production and distribution of artisanal, medicinal mushrooms and associated consumer packaged goods. It offers Amanita Muscaria Tincture, which soothes the body, tackles physical distress, reduce stress, ease muscular tension, and promotes restorative sleep. The company was formerly known as Duncan Park Holdings Corporation and changed its name to Psyched Wellness Ltd. in July 2020. Psyched Wellness Ltd. was incorporated in 2019 and is based in Toronto, Canada.

How the Company Makes Money

Psyched Wellness generates revenue primarily through the sale of its proprietary mushroom-based health supplements and wellness products. These products are marketed directly to consumers through online platforms and select retail partners. The company may also engage in strategic partnerships and collaborations within the biotechnology and healthcare sectors to expand its market reach and product offerings. Additional revenue streams could potentially include licensing agreements for their proprietary formulations and intellectual property, as well as potential future offerings in the form of wellness services or experiences. However, specific financial data or detailed revenue breakdowns are not publicly disclosed.

Psyched Wellness Financial Statement Overview

Summary

Fast revenue growth off a small base and positive gross margin are positives, and the company has no reported debt. However, results are dominated by very large net losses and persistent negative operating/free cash flow, implying continued funding needs and dilution risk if losses persist.

Income Statement

Revenue is scaling quickly off a small base (up ~74% in 2024 vs. 2023, after strong growth in 2023), and gross margin remains positive (~39% in 2024). However, the business is still deeply unprofitable: 2024 net loss was ~C$4.26M on ~C$0.62M of revenue (net margin ~-684%), with operating losses widening versus 2023. Overall, the top line is improving, but profitability is not yet showing operating leverage.

Balance Sheet

The balance sheet is conservatively financed with no debt reported across the period, which reduces refinancing and interest-rate risk. Equity has been relatively stable and increased in 2024 (equity ~C$7.44M; assets ~C$7.89M). The key weakness is persistent negative returns on equity (roughly -57% in 2024), signaling continued value dilution risk if losses require additional funding.

Cash Flow

Cash generation remains weak: operating cash flow was negative in every year shown (about -C$3.10M in 2024), and free cash flow was similarly negative (about -C$3.11M in 2024). Free cash flow deterioration in 2024 versus 2023 is a concern, and cash burn is substantial relative to the current revenue base—implying ongoing funding needs unless expenses are reduced or revenue scales materially.

Breakdown	TTM	Feb 2025	Feb 2024	Feb 2023	Feb 2022	Nov 2020
Income Statement
Total Revenue	451.56K	623.16K	321.10K	14.27K	0.00	0.00
Gross Profit	159.32K	241.89K	155.71K	7.54K	0.00	-10.00K
EBITDA	-5.49M	-4.52M	-3.32M	-4.29M	-65.14K	-2.05M
Net Income	-4.87M	-4.26M	-3.43M	-4.30M	-4.50M	-2.08M
Balance Sheet
Total Assets	5.74M	7.89M	7.34M	3.31M	6.38M	3.21M
Cash, Cash Equivalents and Short-Term Investments	4.44M	6.36M	6.13M	2.57M	5.53M	2.06M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	398.40K	449.33K	303.56K	198.07K	178.15K	34.85K
Stockholders Equity	5.34M	7.44M	7.03M	3.11M	6.20M	3.18M
Cash Flow
Free Cash Flow	-3.41M	-3.11M	-3.11M	-3.18M	-3.04M	-2.31M
Operating Cash Flow	-3.40M	-3.10M	-3.03M	-3.09M	-3.01M	-2.31M
Investing Cash Flow	-5.30K	-2.78K	-44.84K	126.99K	-28.58K	0.00
Financing Cash Flow	0.00	3.39M	6.64M	0.00	6.51M	4.37M

Psyched Wellness Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PSYC, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.28 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PSYC.

Psyched Wellness Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JWEL	73 Outperform	C$1.56B	25.27	13.44%	2.67%	11.25%	58.21%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
PSYC	47 Neutral	C$2.89M	-0.65	-70.53%	―	-41.18%	17.65%
HBFG	45 Neutral	C$237.99M	-99.45	-95.27%	―	212.16%	-46.40%
CULT	42 Neutral	C$587.13K	-0.07	-190.55%	―	―	-126.28%

Psyched Wellness Corporate Events

Psyched Wellness Unveils Potent New Product ‘Calmer’ and Enhances ‘Calm’

Psyched Wellness has launched ‘Calmer,’ a new product that offers twice the potency of its flagship product, ‘Calm,’ and has improved the flavor profile of ‘Calm’ to reduce the mushroom taste. This launch is part of a broader strategy to expand market partnerships in Canada and the United States, and coincides with a Black Friday promotion offering significant discounts. The introduction of ‘Calmer’ and the flavor enhancement of ‘Calm’ are expected to strengthen Psyched Wellness’s position in the dietary supplements industry by addressing consumer feedback and enhancing product appeal.

Psyched Wellness Announces Product Launches and Regulatory Updates

Psyched Wellness has provided an investor update detailing significant progress in product development, scientific studies, and regulatory compliance. The company has launched a new dietary supplement shot called Santa and completed studies confirming the extended shelf life of its AME-1 extract. Despite an FDA response questioning safety data, Psyched Wellness remains confident in the safety of AME-1 and plans to expand market partnerships.